172,047 research outputs found
Cibali
No full textTesto e disegni sul Masterplan elaborato durante il Workshop "intersections_2010" dal Gruppo di lavoro guidato da Roberto Collovà e Gaetano Licata e relativo all'area degli impianti sportivi Cibali a Catania. L'ipotesi centrale del Masterplan, a partire dallo spostamento di parte della linea ferrata a raso esistente (Circumetnea) in sede sotterranea (Metropolitana)- si fonda sulla urbanizzazione dello stadio esistente attraverso l'addizione di nuovi funzioni che lo trasformino in un macroedificio a uso misto e lo integrino con il tessuto edilizio del Borgo di Cibali. Il libro raccoglie i progetti dei 7 gruppi che hanno partecipato al Workshop, tra cui Kengo Kuma, Manuel Aires Mateus, Henri Bava
Gli effetti dell’emigrazione di ieri sullo spopolamento e l’invecchiamento dell’Italia di oggi
No full textIntroduction
No full textThe book is devoted to three key questions concerning the relationship between complexity and natural language. Briefly, such questions are:
(a) What kind of complexity for natural language?
(b) Which theory of language in the perspective of complexity?
(c) What sorts of methods and models in the analysis of the observed phenomena?
All the essays in this volume show the reference to complexity as a constant element. However, the use of the singular may not be entirely appropriate
When and how to treat acute hepatitis C?
No full textBackground: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. Aim: To assess the effectiveness of interferon as treatment for acute hepatitis C by meta-analysis. Methods: MEDLINE search (1985-2002) was supplemented with manual searches of reference lists. Studies were included if they were controlled trials comparing interferon to no treatment and if they included patients with either post-transfusion or sporadic acute hepatitis C. Twelve trials were analyzed (414 patients). The outcome assessed was the sustained virological response (SVR) rate (undetectable hepatitis C virus RNA in serum at least 6 months after cessation of therapy). Results: Interferon significantly increased the SVR (risk difference 49%; 95% confidence interval 32.9-65%) in comparison to no treatment. The risk difference of SVR increased from 5 to 90% when trials were ordered by increasing interferon weekly dose. Delaying therapy by 8-12 weeks after the onset of disease does not compromise the SVR rate. Conclusions: Current evidence is sufficient to recommend interferon treatment of patients with acute hepatitis C. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the 1st month is the best option of treatment. © 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved
Un anello ebraico in bronzo da Porto Torres (sec. IV-V e.v.), e l'epigrafe di Anabatia rinvenuta a Gerace (sec. XIV), con una nota su una lucerna funeraria ebraica da Licata (secc. IV-V e.v.)
No full textThe study presents a number of new archaeological discoveries of Jewish artifacts and proposes a new reading of an already known inscription. Perani, author of Part I, describes a recently discovered Jewish bronze ring from Porto Torres, Sardinia, dating to late antiquity (4th-5th centuries e.v.), relating to similar Jewish rings, discovered in Sicily and Sardinia in the past. Colafemmina, author of Part II, presents his reading of the inscription of Anabatyya found in 1990 in Gerace, province of Reggio Calabria. Finally, M.S. Rizzo and A. Toscano Raffa describe a recently discovered Jewish funerary lamp with menorah from late Roman period (4th-5th centuries), just found in Licata (Sicily)
When and how to treat acute hepatitis C?
No full textBackground: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. Aim: To assess the effectiveness of interferon as treatment for acute hepatitis C by meta-analysis. Methods: MEDLINE search (1985-2002) was supplemented with manual searches of reference lists. Studies were included if they were controlled trials comparing interferon to no treatment and if they included patients with either post-transfusion or sporadic acute hepatitis C. Twelve trials were analyzed (414 patients). The outcome assessed was the sustained virological response (SVR) rate (undetectable hepatitis C virus RNA in serum at least 6 months after cessation of therapy). Results: Interferon significantly increased the SVR (risk difference 49%; 95% confidence interval 32.9-65%) in comparison to no treatment. The risk difference of SVR increased from 5 to 90% when trials were ordered by increasing interferon weekly dose. Delaying therapy by 8-12 weeks after the onset of disease does not compromise the SVR rate. Conclusions: Current evidence is sufficient to recommend interferon treatment of patients with acute hepatitis C. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the 1st month is the best option of treatment. © 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved
Role of the CMS electromagnetic calorimeter in the hunt for the Higgs boson through the two-gamma decay mode
No full textThe Electromagnetic Calorimeter (ECAL) of the Compact Muon Solenoid (CMS) experiment at the LHC is a hermetic, fine grained, homogeneous calorimeter, comprising 75,848 lead tungstate scintillating crystals, located inside the CMS superconducting solenoidal magnet. The scintillation light is detected by avalanche photodiodes in the barrel section and by vacuum phototriodes in the two endcap sections. A silicon/lead pre-shower detector is installed in front of the endcaps in order to improve gamma/pi0 discrimination. Precise calibration of the ECAL detector is required. This includes inter-calibration, to account for the differing response of channels, and calibration of the energy scale. The performance obtained during the first LHC physics runs in 2010 and 2011 is presented and the role of the ECAL in the hunt for the Higgs boson, through the two-gamma decay mode, is discussed
Acute hepatitis C: in search of the optimal approach to cure.
No full textAbstract
IFN monotherapy for acute hepatitis C can be supported, but a strategy taking into account both baseline (clinical presentation, genotype, HIV coinfection) and early (spontaneous viral decay) virologic response should be developed from carefully conducted, controlled prospective studies comparing a “wait and see strategy”, and different schedules of PEG IFN monotherapy to optimize adherence and costs and to reduce the number needed to treat. The price of the ultimate success of therapy for AVH due to HCV, i.e. a stable and definitive clearance of HCV with no residual liver disease in the long term, should not be paid by a high number of patients who are treated needlessly
Treatment of hepatitis C: critical appraisal of the evidence
No full textChronic hepatitis C virus infection is currently the most common cause of end stage liver disease worldwide. Although the conclusions of the last National Institutes of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues remain unanswered. This paper reviews the available data using an evidence-based approach. Current evidence is sufficient to recommend IFN treatment for all patients with acute hepatitis. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during month 1 is the best treatment option. The current gold standard of efficacy for treatment-naive patients with chronic hepatitis C is the combination of pegylated IFN and ribavirin. The overall sustained viral response rate to these regimens is 54 - 56% following a 48-week course of therapy. Patients with genotype 1 infection will have a 42 - 51% likelihood of response to 48weeks of therapy. Those with genotypes 2 or 3 infection will respond to 24weeks in 78 - 82% of cases. Debate continues regarding the optimal dose and duration of peginterferon (PEG-IFN), not only in patients infected with genotype 2 or 3 but also in those infected with genotype 1. The optimal dose of ribavirin has yet to be determined. Available data show the need to give the highest tolerable doses (1000-1200mg/day) to the difficult-to-treat patients (genotype 1, cirrhotics, obese), although there is a greater likelihood of intolerance. Genotypes 2 and 3 may receive 800mg/day, which is also the most appropriate lower dose for those patients who require dosage modification for anaemia or other side effects. Tolerability and compliance to therapy are still a problem, as approximately 15- 20% of patients within trials and > 25% in clinical practice withdraw from therapy. New PEG-IFNs are more effective than conventional IFN in improving liver histology. Monotherapy with PEG-IFN induces a marked reduction in staging in virological sustained responders, and to a lesser degree in relapsers, but provides no benefit to nonresponders after 24-48weeks of treatment. The use of maintenance therapy in virological nonresponders aiming to improve histology should be considered experimental and of unproven benefit. Pooling data from the literature suggests a slight preventive effect of IFN on hepatocellular carcinoma development in patients with HCV-related cirrhosis. The magnitude of this effect is low and the observed benefit may be due to spurious associations. The preventive effect is more evident among sustained responders to IFN
- …
